COVID-friendly’ cancer care at home extended for more patients
Access to cancer therapy drugs previous approved by NHS England in March last year for temporary use during COVID-19 to reduce hospital visits has been extended until the summer, with the potential to extend until the end of March next year.
Source:
NHS England
Resource links:
NHS England interim treatment options during the COVID-19 pandemic
SPS commentary:
Approved treatment options under this guidance include venetoclax in acute myeloid leukaemia as an oral alternative to more toxic standard chemotherapy, nivolumab or pembrolizumab for patients with bowel cancer whose cancers have a specific genetic fingerprint, and ixazomib in myeloma as an oral alternative to treatment which would require more hospital visits and injections.
The list is described in NICE NG161: COVID-19 rapid guideline: delivery of systemic anticancer treatments